Saturday 17 October 2026
Export LGVN’s income statement to Excel — free account
Longeveron Inc.
LGVN Healthcare Biotechnology
Longeveron Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 49.9% from fiscal 2024. In the quarter to June 2026, revenue fell 9.18%, EPS grew 42.4% and free cash flow fell 49.1%, each against the same quarter a year earlier.
1.39
0.11
−7.33%
Follow LGVN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
18.58 | 21.20 | 7.42 | 9.59 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.90) | (5.90) | (1.68) | (2.73) | |
P/B ratio |
2.12 | 1.61 | 1.57 | 1.38 | |
Price to Tangible BV |
2.69 | 1.87 | 2.62 | 1.80 | |
EV/Sales |
10.75 | 8.88 | 3.68 | 3.73 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.63) | (0.59) | (0.24) | (0.32) | |
EV/FCF |
(0.61) | (0.57) | (0.23) | (0.31) | |
Quick Ratio |
2.35 | 3.64 | 1.17 | 1.88 | |
Current Ratio |
2.63 | 3.88 | 1.33 | 2.09 | |
Net Debt/EBITDA |
1.69 | 3.31 | 0.88 | 1.31 | |
Debt/Assets |
0.00% | 3.67% | 1.65% | 0.00% | |
Debt/Equity |
0.00 | 0.05 | 0.03 | 0.00 | |
Asset Turnover |
0.07 | 0.06 | 0.07 | 0.06 | |
Operating CF/Net income |
0.93 | 0.92 | 0.97 | 0.70 | |
Capex/Depreciation |
(0.47) | (0.08) | (0.23) | (0.45) | |
Research and Development Expense of Revenue |
1,112.89% | 582.66% | 745.21% | 2,811.68% | |
Selling, General and Administrative Expense of Revenue |
1,100.70% | 683.42% | 804.38% | 2,615.33% | |
Intangible Assets out of Total Assets |
0.14 | 0.11 | 0.22 | 0.15 | |
Share Based Compensation of Revenue |
129.97% | 95.23% | 103.01% | 327.01% | |
Graham Net Nets |
0.28 | 0.45 | 0.10 | 0.34 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(140.83%) | (108.65%) | (252.96%) | (39.24%) | |
Free Cash Flow Yield |
(94.48%) | (72.97%) | (216.33%) | (126.10%) | |
Revenue per Share |
0.09 | 0.16 | 0.21 | 0.07 | |
Operating CF per Share |
(1.80) | (1.76) | (3.01) | (2.75) | |
Capex per Share |
(0.03) | (0.01) | (0.04) | (0.06) | |
Free Cash Flow per Share |
(1.83) | (1.77) | (3.05) | (2.82) | |
Cash per Share |
3.21 | 6.36 | 2.65 | 5.03 | |
Shareholders Equity per Share |
3.32 | 6.47 | 3.23 | 5.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.32 | 6.47 | 3.23 | 5.42 | |
Free Cash Flow |
(5.76) | (4.39) | (5.36) | (5.17) | |
Working Capital |
7.02 | 12.51 | 1.36 | 5.40 | |
Capital Expenditures |
(0.10) | (0.02) | (0.06) | (0.12) | |
Net Current Asset Value |
6.24 | 11.67 | 0.87 | 4.75 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.36 | 0.05 | 0.18 | 0.86 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.05 | 0.05 | 0.09 | 0.22 | |
Average Payables |
0.67 | 0.33 | 0.26 | 0.98 | |
Average Assets |
16.12 | 21.03 | 17.91 | 22.73 | |
Average Common Equity |
11.53 | 16.59 | 13.78 | 17.80 |
Columns are period end dates